ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

HCID 178418361、化合物 → HCID 178508903、化合物

HRID 1576745
ノート
印刷プレビュー

反応式

HRID 1576745 の反応式
[CH:1]1[C:6]([C:7]([NH:9][C@H:10]([C:16]([OH:18])=[O:17])[CH2:11][CH2:12][C:13]([OH:15])=[O:14])=[O:8])=[CH:5][CH:4]=[C:3]([NH:19][CH2:20][CH2:21][C:22]2[N:27]=[C:26]3[C:28]([N:30]=[C:31]([NH2:33])[NH:32][C:25]3=[N:24][CH:23]=2)=[O:29])[CH:2]=1.[H][H]>[Pt]=O>[CH:5]1[C:6]([C:7]([NH:9][CH:10]([C:16]([OH:18])=[O:17])[CH2:11][CH2:12][C:13]([OH:15])=[O:14])=[O:8])=[CH:1][CH:2]=[C:3]([NH:19][CH2:20][CH2:21][C@@H:22]2[NH:27][C:26]3[C:28]([OH:29])=[N:30][C:31]([NH2:33])=[N:32][C:25]=3[NH:24][CH2:23]2)[CH:4]=1
参加物実験手順出典と根拠反応ノート

参加物

4

反応物 2

HCID 178418361HCID 178418361、化合物HCID 178508921HCID 178508921、化合物

生成物 1

HCID 178508903HCID 178508903、化合物

試薬・触媒・溶媒 1

HCID 82844Platinum oxide (PtO)触媒

実験手順

The preparation of N5 -methyltetrahydrohomofolic acid and alkali metal salts thereof is from homofolic acid starting material (HFA) by catalytic reduction with platinum oxide in the dark under hydrogen at a slight overpressure to produce tetrahydrohomofolate (THHF), them immediately reacting this product with formaldehyde to produce 5,11-methylenetetrahydrohomofolate and reducing this methylene intermediate without isolation with sodium borohydride to give the desired 5-methyltetrahydrohomofolate in the disodium salt form. The 5-methyl product is recovered by precipitating side products at a pH of about 3.8 with acetic acid and refrigerating the product filtrate overnight at about 3°-10°C. The filtrate containing the product 5-methyltetrahydrohomofolate (5-MeTHHF) is treated with charcoal, concentrated to an oil and the 5-methyl product is precipitated with absolute ethanol. The 5,11-methylenetetrahydrofolate may be separately recovered and in a second reaction an additional product known as the 5,11-methenyl is formed by reaction with formic acid. These products show increased stability over folate analogues and show biological promise in the treatment of cancer and leukemia as antifolates and specifically against L1210-FR8 tumor in mice.

出典と根拠

ORDレコード
ord-21e9bc796eb547d5b12997b3da79dc96
出典データセット
uspto-grants-1976_09
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US03983118

反応ノート

読み込み中…

このページの内容参加物実験手順出典と根拠反応ノート